International healthcare institutions have emphasized clinical and laboratory research focused on the use of biomarkers in the perinatal period. The optimal biomarker should be easily collectable, reproducible, usable to monitor disease progression and correlate with standard procedures such as imaging techniques. The availability of reference curves specific for the perinatal period should be considered. The ranges of normality for the ideal biomarker should be available for both healthy term and preterm neonates. The ideal biomarker should be identifiable in different biological fluids (e.g. amniotic, cerebrospinal, blood, urine, saliva, milk).
Some limitations of the clinical studies of biomarkers may include the small cohort sizes, the heterogeneity of the population, the lack of specific reference curves for the neonatal period, the time required for results to be ready, and the lack of stratification according to disease severity.
The goal of this Research Topic is the identification and validation of possible biomarkers able to identify premature neonates at higher risk of disease, to allow the stratification of patients according to disease severity and to guide caregivers in daily practice. Research data about laboratory biomarkers in invasive and non-invasive procedures in fluid collection would be of great help for clinicians.
We welcome contributions from researchers about the role of laboratory biomarkers in the perinatal period in order to:
• Provide health care professionals with new diagnostic tools;
• Improve the early identification of cases at higher risk of disease;
• Promote specific preventive or therapeutic treatments;
• Prevent the occurrence of complications;
• Monitor the progression of disease;
• Promote the inclusion of biomarkers in clinical guidelines in the perinatal period.
International healthcare institutions have emphasized clinical and laboratory research focused on the use of biomarkers in the perinatal period. The optimal biomarker should be easily collectable, reproducible, usable to monitor disease progression and correlate with standard procedures such as imaging techniques. The availability of reference curves specific for the perinatal period should be considered. The ranges of normality for the ideal biomarker should be available for both healthy term and preterm neonates. The ideal biomarker should be identifiable in different biological fluids (e.g. amniotic, cerebrospinal, blood, urine, saliva, milk).
Some limitations of the clinical studies of biomarkers may include the small cohort sizes, the heterogeneity of the population, the lack of specific reference curves for the neonatal period, the time required for results to be ready, and the lack of stratification according to disease severity.
The goal of this Research Topic is the identification and validation of possible biomarkers able to identify premature neonates at higher risk of disease, to allow the stratification of patients according to disease severity and to guide caregivers in daily practice. Research data about laboratory biomarkers in invasive and non-invasive procedures in fluid collection would be of great help for clinicians.
We welcome contributions from researchers about the role of laboratory biomarkers in the perinatal period in order to:
• Provide health care professionals with new diagnostic tools;
• Improve the early identification of cases at higher risk of disease;
• Promote specific preventive or therapeutic treatments;
• Prevent the occurrence of complications;
• Monitor the progression of disease;
• Promote the inclusion of biomarkers in clinical guidelines in the perinatal period.